Symphogen is the leader in the development of antibody mixture therapeutics which seek to improve the treatment of serious human diseases. Symphogen’s growing pipeline of cancer programs offers new and unique mechanisms, which target tumors through multiple simultaneous attacks. The result is improved efficacy and the potential to reduce the development of drug resistance.
